Lupin Ltd - LUPIN Share Price

Sector: Pharmaceuticals | ISIN: INE326A01037
₹ 1,616.35 (-0.39%) icon28 Feb, 2024, 12:00:00 AM

Lupin Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 2/28/2024 12:00:00 AM

    ₹ 1616.35 -6.25 -0.39
  • Open
  • ₹ 1,620.15
  • Prev. Close
  • ₹ 1,622.6
  • Turnover(Lac.)
  • ₹ 0
  • Day's High
  • ₹ 1,642.9
  • Day's Low
  • ₹ 1,604.1
  • 52 Week's High
  • ₹ 1,700
  • 52 Week's Low
  • ₹ 628
  • Book Value
  • ₹ 446.73
  • Face Value
  • ₹ 2
  • Mkt Cap (₹ Cr.)
  • 73,645.25
  • P/E
  • 35.71
  • EPS
  • 45.23
  • Divi. Yield
  • 0.25

Lupin Ltd Corporate Actions

24 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

24 Jan , 2024

12:00 AM

25 Oct , 2023

12:00 AM

25 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

21 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

21 Jul , 2023

12:00 AM

04 Jul , 2023

12:00 AM

AGM

Announcement date: 04 Jul , 2023

View Details

09 May , 2023

12:00 AM

Dividend

Dividend amount: 4
Announcement date: 09 May , 2023

View Details

25 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

25 Apr , 2023

12:00 AM


Lupin Ltd News and Update

Image not found
  • 1 day ago |
  • 12:13 AM

A press release issued by One97 Communications Ltd highlighted the appointment of several new members to the PPBL Board

Image not found
Image not found
  • IIFL News Service |
  • 23 February, 2024 |
  • 12:07 AM
Image not found
  • IIFL News Service |
  • 22 February, 2024 |
  • 12:06 AM

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Lupin Ltd SHAREHOLDING SNAPSHOT
29 February , 2024 | 12:34 AM

PROMOTER - TOTAL47.04%

Indian: 46.76%

Foreign: 0.2825%

NON-PROMOTER - TOTAL 52.96%

Institutions: 45.85%

Non-Institutions: 7.11%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Lupin Ltd FINANCIALS

Lupin Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Lupin Ltd

  • M D Gupta
  • Chairman (Non-Executive)
  • Nilesh Deshbandhu Gupta.
  • Managing Director
  • Vinita Gupta
  • Director & Chief Executive Off
  • R V Satam
  • Company Sec. & Compli. Officer
  • Jean-Luc Belingard
  • Independent Director
  • Ramesh Swaminathan
  • Executive Director & CFO
  • Mark D McDade
  • Independent Director
  • K B S Anand
  • Independent Director
  • Punita Kumar Sinha
  • Independent Director

Summary

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments.Lupin Ltd was incorporated in the year 1983 with the name Lupin Chemicals Ltd. In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar. In the year 1989, the company established a joint venture in Thailand, namely Lupin Chemicals (Thailand) Ltd. In the year 1991, they initiated production of Injectable cephalosporin (bulk and dosages) at Mandideep. In the year 1992, the company set up Fermentation Plant at Tarapur, Maharashtra. Also, Sterile Plant for injectable Cephalosporins (bulk) was commissioned at Mandideep.In the year 2001, Lupin Laboratories Ltd was amalgamated with the company and the name was changed to Lupin Ltd. They commenced supply of Cephalosporin bulk actives to their alliance partners in the US. Also, they commissioned a state of the art US FDA approvable oral cephalosporin bulk active plant. In the year 2002, the company commissioned the new Anti-TB facility at Aurangabad. In the year 2003,... Read More


Reports by Lupin Ltd


Reports by Lupin Ltd

Company FAQ

No Record Found